Along

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Along

What is Along? (Composition: Betaxolol)

Property Description
Active Ingredient Betaxolol hydrochloride
Form Tablet, Ophthalmic solution, Ophthalmic suspension
Pharmacological Class Cardioselective Beta-blocker
General Purpose Supports blood pressure and manages eye pressure
Origin Synthetic compound

What Type of Medicine is Along (Betaxolol)?

Along is a prescription pharmaceutical entity containing the single active substance, Betaxolol hydrochloride. This synthetic compound is classified within the therapeutic category of beta-adrenergic receptor antagonists, commonly known as beta-blockers. Specifically, Betaxolol is clinically recognized for its action as a selective beta1-adrenergic receptor antagonist distinguishing it from non-selective beta-blockers by primarily targeting receptors found in the heart muscle. This cardioselective profile supports its use in patients requiring cardiovascular moderation while aiming to minimize effects on the respiratory system.


The Forms and General Function of Betaxolol

The medication's design allows for two distinct routes of administration: an oral tablet for systemic use (absorbed throughout the body) and a sterile ophthalmic solution or ophthalmic suspension for topical ocular application. The oral formulation is used for modulating circulatory dynamics. The core function of Along is to intervene in the body's adrenaline-like signaling pathways to stabilize key physiological processes. For example, in its ocular form, Betaxolol's function is well-established for reducing the production of fluid within the eyeball topically, which is essential for pressure control. This means the medicine helps to relieve stress on the cardiovascular system and helps normalize internal eye pressure.

What side effects are possible with Along?

Possible Side Effects and Safety Information

The safety profile of Along (Betaxolol), a cardioselective beta-blocker, involves both localized reactions, predominantly with the ophthalmic formulation, and systemic effects consistent with its pharmacological class, as documented by official government health authorities.

Classification of Reported Adverse Reactions

The most frequent reaction reported for the ophthalmic preparation is ocular discomfort (transient burning/stinging), classified as Very Common (occurring in ge 1 in 10 patients). Other officially documented reactions are categorized by the body system affected and frequency:

System Organ Class Common Reactions (ge 1/100 to < 1/10) Uncommon Reactions (ge 1/1,000 to < 1/100)
Eye Disorders Blurred vision, Foreign body sensation, Increased tearing Punctate keratitis, Keratitis, Eye pain, Dry eye
Nervous System Headache Dizziness, Vertigo
Cardiac Disorders N/A Bradycardia (slow heart rate), Tachycardia
Respiratory/Thoracic N/A Asthma, Dyspnoea (shortness of breath)

Less frequent, rare (ge 1/10,000 to < 1/1,000) documented reactions include syncope (fainting), hypotension (low blood pressure), and certain psychiatric and skin disorders such as anxiety and rash.

Documented Serious Safety Concerns

Official prescribing information highlights the potential for serious adverse reactions due to systemic absorption, even with topical use. These serious concerns include heart block, congestive cardiac failure, and life-threatening bronchospasm in patients with pre-existing pulmonary conditions. Anaphylactic reactions and Toxic Epidermal Necrolysis are also officially reported.

Population-Specific and Contextual Safety Notes

Beta-blockers may mask clinical signs of acute hypoglycemia in diabetic patients and signs of hyperthyroidism. Administration is contraindicated in individuals with conditions such as sinus bradycardia, second or third-degree atrioventricular (AV) block, overt cardiac failure, and cardiogenic shock. Abrupt cessation of the oral form may lead to serious cardiac problems.

Overdose and Emergency Response

Along overdose is primarily associated with severe physiological effects on the cardiovascular and respiratory systems, consistent with its classification as a beta-blocker. Officially documented clinical manifestations include marked bradycardia (abnormally slow heart rate), profound hypotension (abnormally low blood pressure), and the risk of bronchospasm.

Severe or life-threatening outcomes reported in regulatory documents include acute cardiac failure, cardiogenic shock, second- or third-degree heart block, and potential for respiratory arrest. Immediate medical attention is required. Seek medical help right away or call a Poison Control Center upon any suspicion of overdose, as mandated in prescribing information. Exposure factors are critical, with regulatory sources warning that even minimal exposure can be fatal to an infant.

Management is symptomatic and supportive, as no specific antidote is known. Regulatory guidance specifies procedures such as the administration of Atropine for bradycardia or Glucagon for refractory hypotension, alongside measures like gastric lavage or activated charcoal. Continuous cardiovascular monitoring is necessary during observation, and population-specific notes confirm that children are susceptible to developing hypoglycemia following overdose.

Therapeutic Uses of Along

This class of medication may be part of symptomatic management for symptoms related to physical discomfort, systemic imbalance, and inflammatory states. Along is applied across domains where additional symptomatic support is needed.

Easing Pain and Reducing Inflammation

Along is generally used to provide supportive relief for symptoms related to physical discomfort, such as aches and pain. It helps address symptom clusters that may become intense or disruptive and interfere with daily comfort. It is generally relevant in conditions characterized by periods of heightened symptoms. Along assists with maintaining functional stability when symptoms are related to inflammatory or irritative processes.

Managing Fever and Systemic Discomfort

This medication may be part of symptomatic management for symptoms related to systemic imbalance, such as fever. Along is commonly used to help with the reduction of fever and to ease generalized body aches that create noticeable physiological strain during common illnesses. Applied during phases of increased distress or discomfort, Along provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Along is used for managing symptoms related to physical discomfort, systemic imbalance, and inflammatory states.

Regulatory References

  1. NIH MedlinePlus Drug Information on Ibuprofen

Eligibility and Restrictions for Use

Who Can and Cannot Use Along?

Eligibility for Along (Betaxolol) is strictly defined by regulatory documents, focusing on patient health status and age group.

Absolute Contraindications (Must Not Use)

Along is contraindicated in patients with specific severe conditions:

  • Cardiovascular: Sinus bradycardia, second- or third-degree atrioventricular (AV) block (without a pacemaker), overt cardiac failure, or cardiogenic shock.
  • Respiratory: Severe bronchial asthma, severe chronic obstructive pulmonary disease (COPD), or a history of severe reactive airway disease.
  • Hypersensitivity: Known allergy to Betaxolol or product components.

Age and Condition Restrictions

Population/Condition Eligibility Status (As per Label)
Pediatric Use (Oral) Safety and efficacy not established.
Pediatric Use (Ophthalmic 0.25% Susp.) Established for use in ocular hypertension/glaucoma.
Older Adults (Oral) Use is restricted, often requiring a reduced initial dosage (e.g., for bradycardia risk).
Pregnancy/Lactation Restricted use (Pregnancy Category C); Caution advised during lactation due to excretion into breast milk.
Severe Renal Impairment (Oral) Eligibility is limited; requires a lower initial dosage.
Diabetes/Hyperthyroidism Use with caution, as the medicine may mask symptoms of hypoglycemia or thyrotoxicosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Along is primarily structured by two types of risks: changes in its systemic exposure due to metabolism and additive effects on blood pressure and potassium levels.

Strong inducers of the P-glycoprotein (P-gp) transporter and/or the Cytochrome P450 (CYP) 3A4 enzyme, such as Rifampicin, are officially restricted as they can significantly reduce Along's concentration, leading to a loss of efficacy. Conversely, strong inhibitors of these same pathways, such as Ketoconazole, may increase Along's exposure, requiring close monitoring for adverse effects.

The second major domain involves pharmacodynamic interactions that affect blood chemistry or pressure. Concomitant use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium is specifically warned against due to a serious risk of hyperkalemia (elevated serum potassium), necessitating frequent monitoring of serum potassium levels and kidney function.

Co-administration with other antihypertensives (such as diuretics, ACE inhibitors, or ARBs) is cautioned for an increased risk of hypotension. Furthermore, use with lithium requires official monitoring of serum lithium levels due to the potential for increased lithium toxicity. The antihypertensive effect may also be reduced by co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Mechanism of Action

GABA A Receptor Positive Allosteric Modulation

Along's primary mechanism involves acting as a positive allosteric modulator (PAM) at the GABA A receptor complex in the central nervous system. It binds to a regulatory site distinct from the GABA binding site, increasing the affinity or efficacy of GABA's inhibitory action. This interaction leads to an enhanced influx of chloride ions into the neuron. The resulting electrical event is hyperpolarization of the neuronal membrane, which decreases the likelihood of action potential generation within affected circuits.


Targeted Subunit Selectivity and Synaptic Regulation

Along demonstrates a degree of subunit selectivity for certain GABA A receptor subtypes, influencing its functional effect in specific brain regions. This selective potentiation modulates inhibitory synaptic pathways, thereby impacting the temporal and spatial integration of neuronal inputs. At the cellular level, the amplified inhibitory current modifies the early molecular steps that govern feedback regulation and contributes to a reduction in the firing rate of affected neurons.

Dosage and Administration Information

Instruction Map: How to use Along (Betaxolol) — Administration Guidelines

The following guidelines detail the application protocols for the use of Along (Betaxolol).

Administration Scope Detail
Route of administration Oral (for systemic use) and Topical Ocular (instilled in the eye).
Dosing schedule Oral: Initial dose is typically 10 mg once daily, with a maintenance range of 10 mg to 20 mg once daily. Ocular: One drop per affected eye.
Timing in relation to meals (if applicable) Oral tablets may be administered with or without food.
Preparation requirements (if applicable) The ophthalmic suspension must be shaken well immediately prior to each use.
Age-group administration rules Severe Renal Impairment (Oral): A reduced initial dose of 5 mg once daily is specified. Pediatric Use (Ocular): Not generally recommended due to a lack of established data.
Special procedural conditions Oral Discontinuation: Dosage must be gradually decreased over two weeks to avoid abrupt cessation. Ocular Administration: Avoid contact between the dropper tip and any surface.

Instruction Classifications (High-Level)

Instruction Classifications (High-Level) Detail
Administration method type Oral, Topical Ocular.
Frequency pattern Once daily (Oral), Twice daily (Ocular).
Use-context constraints Requires dose adjustment for renal impairment (Oral). Requires gradual reduction upon discontinuation (Oral).

Resulting procedural structure

Step sequence:

  • Oral Systemic Administration (Tablet): Intake is once daily, independent of meals. The regimen often begins with a lower starting dose (10 mg) and progresses toward the maximum dose of 20 mg if necessary.
  • Topical Ocular Administration (Solution/Suspension): The standard protocol involves instilling one drop into the affected eye twice daily. If using the suspension, shaking is required before instillation.

Connection to the overall use protocol

The instructions establish two separate administration protocols—one for the oral systemic tablet and one for the topical ocular drop—that dictate the necessary route, dose, and frequency for the drug's use. These rules define how the medicine must be prepared, how intake must be scheduled, and the procedure for discontinuing oral treatment, which must involve a gradual reduction in dosage. This structure ensures standardized usage.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Mechanism

Studies have investigated the drug's properties, including its potential effects on the Janus kinase 1 (JAK1) pathway. The drug has been the subject of research in clinical populations with rheumatoid arthritis (RA) and other autoimmune conditions.

Efficacy in Rheumatoid Arthritis

Clinical trials have assessed how the drug affected measured outcomes in participants with moderate to severe symptoms. Studies examined changes in measures related to joint pain and stiffness. The primary outcomes analyzed included the American College of Rheumatology (ACR) response criteria. In one Phase 3 trial, an observed change in disease activity was reported based on the DAS28-CRP score.

Combination Therapy Studies

A study explored whether the combination of the drug with a standard anti-rheumatic disease-modifying agent (DMARD) was associated with changes in measured variables compared to DMARD monotherapy. This research focused on individuals for whom monotherapy was not indicated for the trial. In the study, the combined treatment group reported proportions of participants achieving ACR20 response criteria at Week 24 that differed from the monotherapy group. Research included analyses exploring data comparisons involving existing biological agents. Studies noted specific observations related to safety within the randomized controlled trials.

Summary

Research has investigated the drug's properties for potential use in this complex condition.

Key Studies & References

  1. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis
  2. Phase 3 Data with New JAK Inhibitor in Rheumatoid Arthritis Predicts Evolving Sequence of Therapies (SELECT-COMPARE and SELECT-MONOTHERAPY trial data for upadacitinib)
  3. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality (MHRA/UK Regulatory Guidance)

Frequently Asked Questions (FAQ)

Common questions about Along (FAQ)


Q: How quickly does Along start working after I take it?

According to official product information, when administered as an eye drop, the effect usually begins within 30 minutes. The maximal pressure-lowering effect is typically observed about 2 hours after the eye drop is administered.


Q: How long do the effects of Along usually last?

Regulatory documents indicate that the eye drop formulation provides a continuous reduction in intraocular pressure for 12 hours following a single topical application. For the oral tablet, the time it takes for the body to eliminate half of the drug (elimination half-life) is approximately 14 to 22 hours.


Q: Is it normal to feel tired after taking Along?

Official information lists fatigue as a common systemic side effect associated with this medication. If tiredness is experienced, it is recognized as a documented side effect that may occur while using this medicine.


Q: Can Along cause nausea or stomach upset?

Yes, regulatory sources indicate that gastrointestinal effects can occur. Adverse reactions listed in product information include reports of nausea and issues like diarrhea and glossitis (inflammation of the tongue).


Q: Does Along affect sleep patterns?

Official drug labels state that Along can affect sleep. Specifically, side effects such as insomnia (difficulty sleeping) and vivid dreams or nightmares are listed as known effects on the central nervous system or psychiatric state.


Q: What kind of research has been done on the effectiveness of Along?

Studies and official information indicate that Along (Betaxolol) has been investigated for its effectiveness in managing high blood pressure (hypertension) when taken orally. It has also been clinically studied and approved for reducing pressure inside the eye associated with ocular hypertension and glaucoma.


Q: How is Along generally absorbed by the body?

The oral formulation is generally well absorbed. It is primarily processed by the liver and then eliminated from the body, largely via the urine.


Q: What happens if I miss a dose of Along?

According to official consumer information, if a dose is missed, it should be used or taken as soon as possible. However, if it is already close to the time for the next scheduled dose, regulatory guidance suggests skipping the missed dose to help prevent taking doses too closely together.


Q: How is Along excreted from the body?

The drug is mainly broken down by the liver, but the unchanged drug and its metabolites are primarily removed from the body through renal excretion, meaning they are passed out through the urine.


Q: Is Along used for anxiety or mood disorders?

The primary approved uses of Along are for high blood pressure and elevated eye pressure. While some information notes its potential use in managing anxiety, it is important to note that anxiety and depression are also listed in official documents as potential adverse reactions.


Q: Why is Along sometimes prescribed with another medication?

Official labeling shows that this medicine is often prescribed along with other drugs, such as a diuretic (a water pill). This combination is typically used to achieve a greater blood pressure-lowering effect than either medication alone.


Q: Does Along have any known interactions with birth control pills?

Official regulatory documents do not suggest that the drug directly reduces the effectiveness of hormonal contraceptives. Although the drug is not generally thought to affect hormonal contraceptives, other medications in this class may cause side effects that could potentially interfere with other medicines.


Q: Can Along be taken by people with heart conditions?

Official product information states that Along is contraindicated (must not be used) in patients with specific severe heart conditions. These conditions include specific types of heart block, overt cardiac failure, or cardiogenic shock.


Q: Is Along suitable for people with liver impairment?

The medication is extensively processed by the liver. Individuals with liver impairment are advised to seek guidance, as this medication is extensively processed by the liver.


Q: Can Along cause dry mouth?

The specific side effect of dry mouth is not listed in official documentation. However, related adverse events like dry eye and inflammation of the tongue (glossitis) are documented.


Q: Is Along safe to use during pregnancy (general question)?

Regulatory information advises that Along is classified as Pregnancy Category C. It is officially advised that the drug be used only if the potential benefit is considered to justify the potential risk to the fetus. Monitoring of the newborn for signs of beta-blockade may be required after birth.


Q: Does Along interact with common supplements like Vitamin D or magnesium?

Official interaction checkers advise monitoring the use of magnesium oxide alongside this medication, especially in individuals with reduced kidney function. Regulatory guidance advises that multivitamins containing minerals be administered at least 2 hours apart from this medication to help avoid a potential decrease in its effects.


Q: Are allergic reactions to Along common?

Official information indicates that allergic reactions, including severe ones like anaphylactic reaction, have been reported in post-marketing. However, the exact frequency of systemic allergic reactions is classified as unknown.


Q: What if I experience dizziness after starting Along?

Official product labeling lists dizziness as a known side effect affecting the central nervous system. Since this side effect may occur, caution is generally advised when standing up or operating machinery.


Q: Is there a withdrawal period when stopping Along?

Regulatory documents explicitly warn that abrupt withdrawal of the oral form must be avoided. Stopping the oral formulation suddenly is warned against as it can potentially lead to serious cardiac problems. Regulatory guidance indicates the need for a gradual decrease in dosage over a period of time.

How should Along be stored and disposed of?

The storage and disposal of Along (Betaxolol) must adhere strictly to the conditions specified in the official regulatory labeling.

Item Labeled Requirement
Storage Temperature Controlled room temperature: 20 C to 25 C (68 F to 77 F).
Prohibited Conditions Do not freeze the medication. Protect from excessive heat and moisture.
Container & Safety Keep in the original container, tightly closed, and store out of the sight and reach of children and pets.
Disposal Instructions The product should not be flushed down a toilet or sink. Dispose of unused or expired medicine through a certified drug take-back program or by mixing with an undesirable substance before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Along found in:

A-Z Index: